Belite Bio Dirección
Dirección controles de criterios 2/4
El CEO de Belite Bio es Tom Lin, nombrado en Nov 2021, tiene una permanencia de 4.5 años. posee directamente un 0.9% de las acciones de la empresa, con un valor de $49.44M. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 4.1 años, respectivamente.
Información clave
Tom Lin
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | 4.5yrs |
| Participación del CEO | 0.9% |
| Permanencia media de la dirección | 4.5yrs |
| Promedio de permanencia en la Junta Directiva | 4.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Oral Retinal Therapy Potential Will Reshape Long Term Outlook For This Pre Revenue Biotech
Catalysts About Belite Bio Belite Bio is a clinical stage biopharmaceutical company focused on oral therapies for retinal and liver diseases. What are the underlying business or industry changes driving this perspective?We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate
Belite Bio (NASDAQ:BLTE) is off 21% in Monday trading after reporting disappointing phase 2 results on tinlarebant for adolescent Stargardt Disease, a rare eye disease characterized by fatty material build-up in the macula. While the company presented the results in a positive light in a Friday evening news release -- a majority of the subjects showed stabilization of visual acuity in at least one eye and no atrophic lesion in 12 of 13 subjects over 12 months of treatment, investors seem less than impressed. Data also showed that fundus autofluorescence imaging indicated no autofluorescence expansion in 7 of 13 participants and 9 of 13 subjects demonstrated a stabilization or improvement in visual acuity. The trial is slated to last for two years.Belite Bio receives approval of begin LBS-008 phase 3 trial in China
Belite Bio (NASDAQ:BLTE) said on Friday it had received approval from the National Medical Products Administration of China to begin the Phase 3 trial of its drug, LBS-008, in adolescent with a rare type of eye disease called Stargardt disease STGD1. A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing. A Phase 3 trial, dubbed dragon, to Evaluate the Safety and Efficacy of LBS-008 in adolescent subjects had begun in the U.S., the United Kingdom, Germany, Belgium, Switzerland, Hong Kong, Taiwan, and Australia, with several patients already enrolled.Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.
Recently IPO’d Belite Bio, Inc (NASDAQ:BLTE) ended a four-day selloff on Monday to climb ~15% after the biopharma company announced the enrollments of its pivotal U.S. Phase 3 clinical trial for lead candidate LBS-008 in patients with eye disorder Stargardt Disease (STGD1). STGD1 has no FDA-approved therapies, and it is the commonest inherited retinal dystrophy that can lead to blurring and/or loss of central vision. LBS-008, an orally administered tablet, is currently undergoing a 2-year Phase 2 trial and a 2-year Phase 3 (DRAGON) trial involving adolescents with STGD1. The company plans to enroll about 60 subjects in the Phase 3 trial which is currently underway in the U.S., U.K., Germany, Belgium, Switzerland, Hong Kong, Taiwan, and Australia. In Q4 2022, BLTE expects to launch a Phase 2/3 trial designed to evaluate the potential of LBS-008 in non-neovascular age-related macular degeneration (Dry AMD), another eye condition with no FDA-approved therapies. Read more about BLTE’s upcoming milestones.Belite Bio GAAP EPS of -$0.23 beats by $0.05
Belite Bio press release (NASDAQ:BLTE): 1H GAAP EPS of -$0.23 beats by $0.05. As of June 30, 2022, the company had $48.7M in cash.Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment
Belite Bio (NASDAQ:BLTE) on Tuesday said it had submitted an investigational new drug application to the U.S. FDA to proceed with its phase 3 trial of its oral tablet LBS-008 for the treatment of Stargardt disease (STGD1). STGD1 is a rare genetic eye disease that is characterized by fatty material build up on the macula. Belite Bio (BLTE) said it is currently conducting a 2-year phase 2 trial and a 2-year phase 3 trial of LBS-008 in adolescent STGD1 subjects. The company said its phase 3 trial, called DRAGON, had already been approved for enrollment in the UK, Switzerland, Hong Kong, Taiwan and Australia. U.S.-listed shares of BLTE earlier closed +5.3% at $43.70.CEO
Tom Lin (47 yo)
Dr. Yu-Hsin Lin, also known as Tom, MBA MMed PhD (Med) is the founder and has served as Director of Belite Bio, Inc since March 2018 and its Chairman and served as the Chief Executive Officer since Novembe...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board of Directors & CEO | 4.5yrs | sin datos | 0.90% $ 49.4m | |
| CFO & Director | 6.1yrs | sin datos | 0.76% $ 41.8m | |
| Chief Scientific Officer | 4.5yrs | sin datos | 0.042% $ 2.3m | |
| Chief Medical Officer | 1.7yrs | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de BLTE se considera experimentado (4.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board of Directors & CEO | 8.2yrs | sin datos | 0.90% $ 49.4m | |
| CFO & Director | 4.5yrs | sin datos | 0.76% $ 41.8m | |
| Member of Ophthalmology Clinical Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.1yrs | sin datos | sin datos | |
| Member of Ophthalmology Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Ophthalmology Clinical Advisory Board | no data | sin datos | sin datos | |
| Director | 4.5yrs | sin datos | 0.083% $ 4.5m | |
| Independent Director | 4.1yrs | sin datos | sin datos | |
| Independent Director | 4.1yrs | sin datos | sin datos | |
| Director | 1.1yrs | sin datos | 0.0010% $ 56.1k | |
| Member of Ophthalmology Clinical Advisory Board | no data | sin datos | sin datos |
Junta con experiencia: La junta directiva de BLTE se considera experimentada (4.1 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 12:43 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Belite Bio, Inc está cubierta por 11 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Bruce Jackson | Benchmark Company |
| Tazeen Ahmad | BofA Global Research |
| Jennifer Kim | Cantor Fitzgerald & Co. |